Lantern Pharma Advances ADC Program Across Multiple Solid Tumor Cancers
Portfolio Pulse from Benzinga Newsdesk
Lantern Pharma is advancing its ADC program for solid tumor cancers, leveraging its RADR® AI platform and a unique conjugation approach. The cryptophycin-based ADC has shown high potency in preclinical tests and is aimed at tumors resistant to current therapies. Lantern plans to move towards IND development in 2024, targeting a market expected to generate over $24 billion by 2030.
February 15, 2024 | 1:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lantern Pharma's advancement in ADC program for solid tumor cancers could position it as a key player in a market expected to reach over $24 billion by 2030.
The advancement of Lantern Pharma's ADC program, leveraging proprietary AI and unique technology, directly impacts its potential market positioning and revenue growth, especially in a high-value market. The focus on solid tumors unresponsive to current therapies could significantly enhance its competitive edge and investor interest.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100